Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fab'BCMA-MORF1
- Development stage
- Preclinical
- Lead developer
- University of Utah
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fab'BCMA-MORF1 is a biologic component of the Multi-Antigen T Cell Hybridizers (MATCH) immunotherapy system, currently under development for the treatment of multiple myeloma. It is a modular T-cell engager component consisting of a Fab' antibody fragment that targets B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells, conjugated to a 25-base morpholino oligonucleotide (MORF1). The MATCH system operates as a two-step, self-assembling bispecific platform: Fab'BCMA-MORF1 first binds to the tumor cells, and subsequently hybridizes with a complementary component (Fab'CD3-MORF2) that targets T-cells. This hybridization creates a functional bridge between the T-cell and the cancer cell, inducing targeted cytotoxicity. This technology, developed by researchers at the University of Utah and the University of Texas at Austin, aims to provide a highly customizable and potentially safer alternative to traditional bispecific antibodies.
- Other names
- Fab'-BCMA-MORF1BCMA-MORF1BCMA-MORF-1BCMA-MORF 1
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on Fab'BCMA-MORF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fab'BCMA-MORF1.